Multi-Infarct Dementia Market By Causes Of Dementia (Anemia, Brain Tumor, Chronic Infection, Depression, Thyroid Disease, Vitamin Deficiency, Drug Intoxication), By Pharmacological Treatment (Cholinesterase Inhibitors (CHEIS), Memantine, Nimodipine, Hydergine, Cytidine 5′-Diphosphocholine (CDP-Choline)) , Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jul 27, 2016

Key Findings


The global multi-infarct dementia market has been expected to grow at the CAGR of 12.7 % during 2016-2022 and it has been expected to reach $13400 million in terms of revenue by 2022.Growing prevalence of blockage and strokes in brain nerves is predictable to be major factor boosting the global multi infarct dementia market.The multi infarct dementia is a series of minor brain strokes which acts as a disruption in the flow of blood in the brain. It is also termed as vascular dementia (VaD).


According to National Institute of Aging, multi-infarct dementia and alzheimer disease is the common form of dementia. This type of diseases are mainly found in elders, 1 out of 3 senior citizens dies with alzheimer diseases or another dementia.Thus, rising geriatric population base globally is also boosting the global multi infarct dementia market. Numerous technological advancements in several inhibitors used for the prevention ofalzheimer’s and dementia is another notable factor anticipated to further acts as a driver boosting the global multi infarct dementia market during the forecasted period. Though, unavailability of treatment for reversing the brain cell damages due to stroke along with the primary focus of therapy on prevention and control of future strokes, has beenanticipated to restrain the growth of the multi infarct dementia market in next few years.


Market Segment Insight


Theglobal multi-infarct dementia market is majorly segmented intocauses of dementia, pharmacological treatment and regional outlook.On the basis of causes of dementia segment, market is divided into anemia, brain tumor, chronic infection, depression, thyroid disease, vitamin deficiency and drug intoxication. Depression cause of dementia is growing at a faster pace, as it affects the person’s brain.In pharmacological treatment segment, market is divided into cholinesterase inhibitors (ChEIs), memantine, nimodipine, hydergine and cytidine 5′-diphosphocholine (CDP-choline). Cholinesterase inhibitors (ChEIs) is subdivided into donepezil, galantamine and rivastigmine. Cholinesterase inhibitors (ChEIs) pharmacological treatment is growing very faster as it is majorly subscribed and consult by neurologist. Cytidine 5′-Diphosphocholine (CDP-choline) is also showing major growth as it is very effective in treating the symptoms of the diseases (though the disease has no cure).


Regional outlook segment is divided into North America, Europe, Asia Pacific and Rest of the World. Asia Pacific region is growing at a faster pace majorly due to rising geriatric population. China and Japan are the major countries in this region. North America has been expected to dominate the global multi-infarct dementia market during the forecasted period. European region follows North America in terms of revenue. Rising aged population, and growing incidences of multi-infarct dementia are the major reason for the growth in North American and European region.


Regional Insight


Globally the global multi-infarct dementia market has been divided into North America, Europe, Asia Pacific and Rest of the World. North American region has been expected to dominate the global multi-infarct dementia market during the forecasted year owing to rise in the incidences of multi infarct dementia coupled with increasing aged population base. European region displayed similar traits and followed North American in terms of growth in the same market. Asia Pacific markethas beenanticipated to grow at a higher pace due to rising awareness against the prevention of brain strokes in this region. Japan alone represents around more than 50% of the dementia and alzheimer’s cases in Asia Pacific region owing to the huge geriatric population base. The developed nations such as Canada, France, Germany, Japan, and U.S. has beenestimated to witness favorable growth over the forecasted period. Rest of the world is showing positive growth rate majorly due to rising aged population, increase in healthcare infrastructure and technological advancement.


Competitive Insights


Some ofthe key market players are GVK bioscience, Celera Corporation, Accelerys Inc., IBM Life science, Siegen Inc., Novartis pharmaceutical corporation, Life technologies corporation, Janssen pharmaceuticals, Inc., etc.Acquisitions, new product development, collaborations, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 13
1.1. RESEARCH METHODOLOGY 13
1.2. RESEARCH SCOPE & ASSUMPTIONS 13
1.3. LIST OF DATA SOURCES 13


CHAP 2. EXECUTIVE SUMMARY 14
2.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET SUMMARY & KEY BUYING CRITERIA 14
2.2. GLOBAL MULTI-INFARCT DEMENTIA MARKET OUTLOOK 14
2.3. MARKET SEGMENTATION ANALYSIS 14
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 14
2.5. GLOBAL MULTI-INFARCT DEMENTIA MARKET VALUE CHAIN ANALYSIS 14
2.6. VENDOR LANDSCAPE 14


CHAP 3. GLOBAL MULTI-INFARCT DEMENTIA MARKET 15
3.1. MARKET DRIVER ANALYSIS 15
3.1.1. RISING GERIATRIC POPULATION 15
3.1.2. GROWING PREVELANCE OF ALZHEIMER DISEASES 15
3.2. MARKET RESTRAINT ANALYSIS 15
3.3. KEY OPPORTUNITIES 15
3.3.1. RISING MRI SCANNING TECHNOLOGY 15
3.4. CHALLENGES 15
3.4.1. NO MEDICINE TO TREAT THE DISEASES COMPLETELY 15
3.4.2. STRINGENT GOVERNMENT REGULATIONS 15


CHAP 4. INDUSTRY ANALYSIS 16
4.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET– PORTER’S FIVE FORCE MODEL 16
4.2. GLOBAL MULTI-INFARCT DEMENTIA MARKET– PESTEL ANALYSIS 16
4.3. GLOBAL MULTI-INFARCT DEMENTIA MARKET– GAP ANALYSIS 16


CHAP 5. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CAUSES OF DEMENTIA 2012-2022 ($ MILLION) 17
5.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY ANEMIA 2012-2022 ($ MILLION) 17
5.2. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY BRAIN TUMOR 2012-2022 ($ MILLION) 17
5.3. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CHRONIC INFECTION 2012-2022 ($ MILLION) 17
5.4. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY DEPRESSION 2012-2022 ($ MILLION) 17
5.5. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY THYROID DISEASE 2012-2022 ($ MILLION) 17
5.6. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY VITAMIN DEFICIENCY 2012-2022 ($ MILLION) 17
5.7. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY DRUG INTOXICATION 2012-2022 ($ MILLION) 17


CHAP 6. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY PHARMACOLOGICAL TREATMENT 2012-2022 ($ MILLION) 18
6.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CHOLINESTERASE INHIBITORS (CHEIS) 2012-2022 ($ MILLION) 18
6.2. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY MEMANTINE 2012-2022 ($ MILLION) 18
6.3. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY NIMODIPINE 2012-2022 ($ MILLION) 18
6.4. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY HYDERGINE 2012-2022 ($ MILLION) 18
6.5. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CYTIDINE 5′-DIPHOSPHOCHOLINE (CDP-CHOLINE) 2012-2022 ($ MILLION) 18


CHAP 7. GLOBAL MULTI-INFARCT DEMENTIA MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 19
7.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY REGION 2012-2022 ($ MILLION) 19
7.2. NORTH AMERICA 19
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 19
7.2.3.1. U.S. 19
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.2.3.2. CANADA 19
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.2.3.3. MEXICO 19
7.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3. EUROPE 20
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
7.3.3.1. GERMANY 20
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.3.3.2. UK 20
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.3.3.3. FRANCE 20
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.3.3.4. SPAIN 20
7.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.3.3.5. ITALY 20
7.3.3.5.1. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.3.3.5.2. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.3.3.6. REST OF EUROPE 21
7.3.3.6.1. REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 21
7.3.3.6.2. REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 21
7.4. ASIA PACIFIC 21
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 21
7.4.3.1. CHINA 21
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.4.3.2. INDIA 21
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.4.3.3. JAPAN 21
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 21
7.4.3.4. SOUTH KOREA 21
7.4.3.4.1. SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
7.4.3.4.2. SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 22
7.4.3.5. REST OF APAC 22
7.4.3.5.1. REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
7.4.3.5.2. REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
7.5. REST OF THE WORLD 22
7.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
7.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
7.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 22
7.5.3.1. LATIN AMERICA 22
7.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
7.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
7.5.3.2. MIDDLE EAST AND AFRICA 22
7.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
7.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22


CHAP 8. COMPETITIVE LANDSCAPE 23
8.1. ACCELERYS INC 24
8.1.2. SCOT ANALYSIS 24
8.1.3. PRODUCT BENCHMARKING 24
8.1.4. STRATEGIC INITIATIVES 24
8.2. AFFYMETRIX 24
8.2.2. SCOT ANALYSIS 24
8.2.3. PRODUCT BENCHMARKING 24
8.2.4. STRATEGIC INITIATIVES 24
8.3. AGILENT TECHNOLOGIES 24
8.3.2. SCOT ANALYSIS 24
8.3.3. PRODUCT BENCHMARKING 24
8.3.4. STRATEGIC INITIATIVES 24
8.4. CELERA CORPORATION 24
8.4.2. PRODUCT BENCHMARKING 24
8.4.3. STRATEGIC INITIATIVES 24
8.5. DNANEXUS 24
8.5.2. SCOT ANALYSIS 24
8.5.3. PRODUCT BENCHMARKING 24
8.5.4. STRATEGIC INITIATIVES 24
8.6. FOREST LABORATORIES, INC. 24
8.6.2. SCOT ANALYSIS 24
8.6.3. PRODUCT BENCHMARKING 25
8.6.4. STRATEGIC INITIATIVES 25
8.7. GENEVA BIOINFORMATIC 25
8.7.2. SCOT ANALYSIS 25
8.7.3. PRODUCT BENCHMARKING 25
8.7.4. STRATEGIC INITIATIVES 25
8.8. GVK BIOSCIENCES 25
8.8.2. SCOT ANALYSIS 25
8.8.3. PRODUCT BENCHMARKING 25
8.8.4. STRATEGIC INITIATIVES 25
8.9. IBM LIFE SCIENCES 25
8.9.2. SCOT ANALYSIS 25
8.9.3. PRODUCT BENCHMARKING 25
8.9.4. STRATEGIC INITIATIVES 25
8.10. ILLUMINA INC. 25
8.10.2. SCOT ANALYSIS 25
8.10.3. PRODUCT BENCHMARKING 25
8.10.4. STRATEGIC INITIATIVES 25
8.11. JANSSEN PHARMACEUTICALS, INC. 25
8.11.2. SCOT ANALYSIS 25
8.11.3. PRODUCT BENCHMARKING 25
8.11.4. STRATEGIC INITIATIVES 25
8.12. LIFE TECHNOLOGIES CORPORATION 26
8.12.2. SCOT ANALYSIS 26
8.12.3. PRODUCT BENCHMARKING 26
8.12.4. STRATEGIC INITIATIVES 26
8.13. NOVARTIS PHARMACEUTICAL CORPORATION 26
8.13.2. SCOT ANALYSIS 26
8.13.3. PRODUCT BENCHMARKING 26
8.13.4. STRATEGIC INITIATIVES 26
8.14. PFIZER, INC. 26
8.14.2. SCOT ANALYSIS 26
8.14.3. PRODUCT BENCHMARKING 26
8.14.4. STRATEGIC INITIATIVES 26
8.15. SIEGEN INC. 26
8.15.2. SCOT ANALYSIS 26
8.15.3. PRODUCT BENCHMARKING 26
8.15.4. STRATEGIC INITIATIVES 26

TABLE 1 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CAUSES OF DEMENTIA 2012-2022 ($ MILLION) 26
TABLE 2 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY ANEMIA 2012-2022 ($ MILLION) 26
TABLE 3 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY BRAIN TUMOR 2012-2022 ($ MILLION) 26
TABLE 4 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CHRONIC INFECTION 2012-2022 ($ MILLION) 27
TABLE 5 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY DEPRESSION 2012-2022 ($ MILLION) 27
TABLE 6 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY THYROID DISEASE 2012-2022 ($ MILLION) 27
TABLE 7 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY VITAMIN DEFICIENCY 2012-2022 ($ MILLION) 27
TABLE 8 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY DRUG INTOXICATION 2012-2022 ($ MILLION) 27
TABLE 9 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY PHARMACOLOGICAL TREATMENT 2012-2022 ($ MILLION) 27
TABLE 10 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CHOLINESTERASE INHIBITORS (CHEIS) 2012-2022 ($ MILLION) 27
TABLE 11 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY DONEPEZIL 2012-2022 ($ MILLION) 27
TABLE 12 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY GALANTAMINE 2012-2022 ($ MILLION) 27
TABLE 13 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY RIVASTIGMINE 2012-2022 ($ MILLION) 27
TABLE 14 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY MEMANTINE 2012-2022 ($ MILLION) 27
TABLE 15 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY NIMODIPINE 2012-2022 ($ MILLION) 27
TABLE 16 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY HYDERGINE 2012-2022 ($ MILLION) 27
TABLE 17 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CYTIDINE 5′-DIPHOSPHOCHOLINE (CDP-CHOLINE) 2012-2022 ($ MILLION) 27
TABLE 18 GLOBAL MULTI-INFARCT DEMENTIA MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 27
TABLE 19 GLOBAL MULTI-INFARCT DEMENTIA MARKET BY REGION 2012-2022 ($ MILLION) 27
TABLE 20 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 21 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 22 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 28
TABLE 23 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 24 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 25 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 26 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 27 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 28 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 29 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 30 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 31 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 28
TABLE 32 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 33 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 34 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 35 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 36 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 37 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 38 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 39 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 40 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 41 ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 42 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022 ($ MILLION) 29
TABLE 43 REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 44 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 45 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 46 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 29
TABLE 47 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 48 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 49 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 50 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 51 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 52 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 53 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 54 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 55 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 56 REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 57 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 58 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 59 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 30
TABLE 60 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 61 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 62 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 63 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30

FIGURE 1 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 2 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 9 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 10 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022 ($ MILLION) 31
FIGURE 11 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 15 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 16 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 18 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 19 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)